Articulus Bio, LLC, a Boulder, CO-based seed-stage orthopedic medical device company focused on total ankle replacement (TAR), completed a funding round of undisclosed amount.
The group of physician and investor members of AngelMD, a platform that connects medial startups with doctors that provide guidance and investors that provide funding, participated in the round.
Led by Adam Rubenstein, CEO, Articulus Bio is a seed-stage orthopedic medical device company focused on total ankle replacement (TAR). The first area of focus is to address the wear debris issue — either metal on metal or metal on plastic — caused by friction occurring at the articulating faces of joint surfaces.
While the team remains focused on the development of their TAR product, the company has a parallel goal of deploying their platform-based Tendonoid™ Web Joint System across a host of large and small joint sites. The technology utilizes a novel configuration of the previously FDA approved Ultra High Molecular Weight Polyethylene (UHMWPE) biomaterial spun into the Tendonoid Web Joint System structure. The Tendonoid Web Joint System is designed to reduce/eliminate friction/grinding at the articulating joint faces that are observed in prior generations of devices. When the friction/grinding is reduced/eliminated, so too is the wear debris.